AVIR — Atea Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $254.01m
- -$200.71m
- 55
- 44
- 54
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.58 | ||
| Price to Tang. Book | 0.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -43.26% | ||
| Return on Equity | -33.88% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 48.63 | 351.37 | n/a | n/a | n/a | n/a | 5.67 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +1467.39 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
Directors
- Jean-Pierre Sommadossi CHM (65)
- Andrea Corcoran CFO
- Wayne Foster SVF (52)
- Janet Hammond OTH (61)
- Maria Horga OTH (52)
- John Vavricka OTH (57)
- Franklin Berger LED (71)
- Jerome Adams DRC
- Barbara Duncan IND (56)
- Bruno Lucidi IND
- Polly Murphy IND (56)
- Bruce Polsky IND (59)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 12th, 2012
- Public Since
- October 30th, 2020
- No. of Shareholders
- 18
- No. of Employees
- 56
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 85,525,179
- Address
- 225 Franklin Street, Suite 2100, BOSTON, 02110
- Web
- https://ateapharma.com/
- Phone
- +1 8572048109
- Contact
- Jonae Barnes
- Auditors
- KPMG LLP
Upcoming Events for AVIR
Atea Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Atea Pharmaceuticals Inc Earnings Release
Similar to AVIR
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Atea Pharmaceuticals share price?
As of Today at 19:24 UTC, shares in Atea Pharmaceuticals are trading at $2.97. This share price information is delayed by 15 minutes.
How has the Atea Pharmaceuticals share price performed this year?
Shares in Atea Pharmaceuticals last closed at $2.97 and the price had moved by -19.95% over the past 365 days. In terms of relative price strength the Atea Pharmaceuticals share price has underperformed the S&P500 Index by -24.73% over the past year.
What are the analyst and broker recommendations for Atea Pharmaceuticals?
The overall consensus recommendation for Atea Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Atea Pharmaceuticals dividend yield?
Atea Pharmaceuticals does not currently pay a dividend.
Does Atea Pharmaceuticals pay a dividend?
Atea Pharmaceuticals does not currently pay a dividend.
When does Atea Pharmaceuticals next pay dividends?
Atea Pharmaceuticals does not currently pay a dividend.
How do I buy Atea Pharmaceuticals shares?
To buy shares in Atea Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Atea Pharmaceuticals?
As of the previous close price of $2.97, shares in Atea Pharmaceuticals had a market capitalisation of $254.01m.
Where are Atea Pharmaceuticals shares listed?
Here are the trading details for Atea Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AVIR
What kind of share is Atea Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Atea Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Atea Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Atea Pharmaceuticals is $6.00. That is 102.02% above the last closing price of $2.97.
Analysts covering Atea Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.70 for the next financial year.
Find out moreWhat is the trend in the Atea Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atea Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -13.84%.
As of the last closing price of $2.97, shares in Atea Pharmaceuticals were trading -10.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Atea Pharmaceuticals PE Ratio?
The Atea Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.97.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Atea Pharmaceuticals?
Atea Pharmaceuticals' management team is headed by:
- Jean-Pierre Sommadossi - CHM
- Andrea Corcoran - CFO
- Wayne Foster - SVF
- Janet Hammond - OTH
- Maria Horga - OTH
- John Vavricka - OTH
- Franklin Berger - LED
- Jerome Adams - DRC
- Barbara Duncan - IND
- Bruno Lucidi - IND
- Polly Murphy - IND
- Bruce Polsky - IND